RETET Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Retet, and when can generic versions of Retet launch?
Retet is a drug marketed by Solvay and is included in one NDA.
The generic ingredient in RETET is tetracycline hydrochloride. There are ninety-nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the tetracycline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Retet
A generic version of RETET was approved as tetracycline hydrochloride by WATSON LABS on December 31st, 1969.
Summary for RETET
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 84 |
Patent Applications: | 4,504 |
Formulation / Manufacturing: | see details |
DailyMed Link: | RETET at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for RETET
US Patents and Regulatory Information for RETET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Solvay | RETET | tetracycline hydrochloride | CAPSULE;ORAL | 061443-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Solvay | RETET | tetracycline hydrochloride | CAPSULE;ORAL | 061443-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |